The  ||| S:0 E:4 ||| DT
Expression  ||| S:4 E:15 ||| NNP
of  ||| S:15 E:18 ||| IN
microRNA-223  ||| S:18 E:31 ||| NNP
and  ||| S:31 E:35 ||| CC
FAM5C  ||| S:35 E:41 ||| CD
in  ||| S:41 E:44 ||| IN
Cerebral  ||| S:44 E:53 ||| NNP
Infarction  ||| S:53 E:64 ||| NNP
Patients  ||| S:64 E:73 ||| NNPS
with  ||| S:73 E:78 ||| IN
Diabetes  ||| S:78 E:87 ||| NNP
Mellitus  ||| S:87 E:96 ||| NNP
The  ||| S:96 E:100 ||| DT
aim  ||| S:100 E:104 ||| NN
of  ||| S:104 E:107 ||| IN
the  ||| S:107 E:111 ||| DT
study  ||| S:111 E:117 ||| NN
was  ||| S:117 E:121 ||| VBD
to  ||| S:121 E:124 ||| TO
investigate  ||| S:124 E:136 ||| VB
the  ||| S:136 E:140 ||| DT
expression  ||| S:140 E:151 ||| NN
of  ||| S:151 E:154 ||| IN
miR-223  ||| S:154 E:162 ||| NNP
and  ||| S:162 E:166 ||| CC
FAM5C  ||| S:166 E:172 ||| CD
in  ||| S:172 E:175 ||| IN
the  ||| S:175 E:179 ||| DT
peripheral  ||| S:179 E:190 ||| JJ
blood  ||| S:190 E:196 ||| NN
mononuclear  ||| S:196 E:208 ||| NN
cells  ||| S:208 E:214 ||| NNS
( ||| S:214 E:215 ||| -LRB-
PBMCs ||| S:215 E:220 ||| NNP
)  ||| S:220 E:222 ||| -RRB-
of  ||| S:222 E:225 ||| IN
cerebral  ||| S:225 E:234 ||| JJ
infarction  ||| S:234 E:245 ||| JJ
patients  ||| S:245 E:254 ||| NNS
with  ||| S:254 E:259 ||| IN
or  ||| S:259 E:262 ||| CC
without  ||| S:262 E:270 ||| IN
diabetes ||| S:270 E:278 ||| NN
.  ||| S:278 E:280 ||| .
Sixteen  ||| S:280 E:288 ||| JJ
cases  ||| S:288 E:294 ||| NNS
with  ||| S:294 E:299 ||| IN
diabetes  ||| S:299 E:308 ||| JJ
mellitus  ||| S:308 E:317 ||| NNS
( ||| S:317 E:318 ||| -LRB-
DM ||| S:318 E:320 ||| NNP
) ||| S:320 E:321 ||| -RRB-
,  ||| S:321 E:323 ||| ,
14  ||| S:323 E:326 ||| CD
cases  ||| S:326 E:332 ||| NNS
with  ||| S:332 E:337 ||| IN
cerebral  ||| S:337 E:346 ||| JJ
infarction  ||| S:346 E:357 ||| NNS
( ||| S:357 E:358 ||| -LRB-
CI ||| S:358 E:360 ||| NNP
) ||| S:360 E:361 ||| -RRB-
,  ||| S:361 E:363 ||| ,
12  ||| S:363 E:366 ||| CD
cases  ||| S:366 E:372 ||| NNS
with  ||| S:372 E:377 ||| IN
cerebral  ||| S:377 E:386 ||| JJ
infarction  ||| S:386 E:397 ||| NN
and  ||| S:397 E:401 ||| CC
diabetes  ||| S:401 E:410 ||| JJ
mellitus  ||| S:410 E:419 ||| NNS
( ||| S:419 E:420 ||| -LRB-
CIDM ||| S:420 E:424 ||| NNP
) ||| S:424 E:425 ||| -RRB-
,  ||| S:425 E:427 ||| ,
and  ||| S:427 E:431 ||| CC
18  ||| S:431 E:434 ||| CD
healthy  ||| S:434 E:442 ||| JJ
subjects  ||| S:442 E:451 ||| NNS
were  ||| S:451 E:456 ||| VBD
included  ||| S:456 E:465 ||| VBN
in  ||| S:465 E:468 ||| IN
this  ||| S:468 E:473 ||| DT
study ||| S:473 E:478 ||| NN
.  ||| S:478 E:480 ||| .
Real-time  ||| S:480 E:490 ||| JJ
PCR  ||| S:490 E:494 ||| NNP
was  ||| S:494 E:498 ||| VBD
used  ||| S:498 E:503 ||| VBN
to  ||| S:503 E:506 ||| TO
quantify  ||| S:506 E:515 ||| VB
mRNA  ||| S:515 E:520 ||| JJ
expression ||| S:520 E:530 ||| NN
.  ||| S:530 E:532 ||| .
Western  ||| S:532 E:540 ||| JJ
blot  ||| S:540 E:545 ||| NN
was  ||| S:545 E:549 ||| VBD
used  ||| S:549 E:554 ||| VBN
to  ||| S:554 E:557 ||| TO
detect  ||| S:557 E:564 ||| VB
FAM5C  ||| S:564 E:570 ||| CD
protein  ||| S:570 E:578 ||| NN
level ||| S:578 E:583 ||| NN
.  ||| S:583 E:585 ||| .
Recombinant  ||| S:585 E:597 ||| FW
plasmids  ||| S:597 E:606 ||| FW
expressing  ||| S:606 E:617 ||| FW
miR-223-3p  ||| S:617 E:628 ||| FW
and  ||| S:628 E:632 ||| CC
3 ||| S:632 E:633 ||| CD
'  ||| S:633 E:635 ||| POS
UTR  ||| S:635 E:639 ||| NNP
of  ||| S:639 E:642 ||| IN
FAM5C  ||| S:642 E:648 ||| NNP
were  ||| S:648 E:653 ||| VBD
constructed ||| S:653 E:664 ||| VBN
.  ||| S:664 E:666 ||| .
Dual-luciferase  ||| S:666 E:682 ||| JJ
reporter  ||| S:682 E:691 ||| NN
system  ||| S:691 E:698 ||| NN
was  ||| S:698 E:702 ||| VBD
used  ||| S:702 E:707 ||| VBN
to  ||| S:707 E:710 ||| TO
analyze  ||| S:710 E:718 ||| VB
the  ||| S:718 E:722 ||| DT
binding  ||| S:722 E:730 ||| NN
of  ||| S:730 E:733 ||| IN
miR-223-3p  ||| S:733 E:744 ||| CD
to  ||| S:744 E:747 ||| TO
FAM5C  ||| S:747 E:753 ||| CD
3 ||| S:753 E:754 ||| CD
'  ||| S:754 E:756 ||| POS
UTR ||| S:756 E:759 ||| NNP
.  ||| S:759 E:761 ||| .
FAM5C  ||| S:761 E:767 ||| NNP
mRNA  ||| S:767 E:772 ||| NNP
and  ||| S:772 E:776 ||| CC
protein  ||| S:776 E:784 ||| NN
level  ||| S:784 E:790 ||| NN
were  ||| S:790 E:795 ||| VBD
significantly  ||| S:795 E:809 ||| RB
higher  ||| S:809 E:816 ||| JJR
in  ||| S:816 E:819 ||| IN
the  ||| S:819 E:823 ||| DT
PBMCs  ||| S:823 E:829 ||| JJ
of  ||| S:829 E:832 ||| IN
CIDM  ||| S:832 E:837 ||| NNP
patients  ||| S:837 E:846 ||| NNS
compared  ||| S:846 E:855 ||| VBN
with  ||| S:855 E:860 ||| IN
healthy  ||| S:860 E:868 ||| JJ
controls  ||| S:868 E:877 ||| NNS
( ||| S:877 E:878 ||| -LRB-
P   ||| S:878 E:880 ||| NNP
< ||| S:880 E:881 ||| SYM
 0.05 ||| S:881 E:886 ||| NNP
) ||| S:886 E:887 ||| -RRB-
.  ||| S:887 E:889 ||| .
miR-223-3p  ||| S:889 E:900 ||| CD
expression  ||| S:900 E:911 ||| NN
in  ||| S:911 E:914 ||| IN
PBMCs  ||| S:914 E:920 ||| NNP
was  ||| S:920 E:924 ||| VBD
significantly  ||| S:924 E:938 ||| RB
lower  ||| S:938 E:944 ||| JJR
in  ||| S:944 E:947 ||| IN
DM  ||| S:947 E:950 ||| NNP
patients  ||| S:950 E:959 ||| NNS
than  ||| S:959 E:964 ||| IN
in  ||| S:964 E:967 ||| IN
healthy  ||| S:967 E:975 ||| JJ
controls  ||| S:975 E:984 ||| NNS
( ||| S:984 E:985 ||| -LRB-
P   ||| S:985 E:987 ||| NNP
< ||| S:987 E:988 ||| SYM
 0.05 ||| S:988 E:993 ||| NNP
) ||| S:993 E:994 ||| -RRB-
.  ||| S:994 E:996 ||| .
The  ||| S:996 E:1000 ||| DT
expression  ||| S:1000 E:1011 ||| NN
of  ||| S:1011 E:1014 ||| IN
miR-223-3p  ||| S:1014 E:1025 ||| NNP
was  ||| S:1025 E:1029 ||| VBD
negatively  ||| S:1029 E:1040 ||| RB
correlated  ||| S:1040 E:1051 ||| VBN
with  ||| S:1051 E:1056 ||| IN
FAM5C  ||| S:1056 E:1062 ||| CD
mRNA  ||| S:1062 E:1067 ||| NN
in  ||| S:1067 E:1070 ||| IN
all  ||| S:1070 E:1074 ||| DT
patients  ||| S:1074 E:1083 ||| NNS
and  ||| S:1083 E:1087 ||| CC
healthy  ||| S:1087 E:1095 ||| JJ
controls ||| S:1095 E:1103 ||| NNS
.  ||| S:1103 E:1105 ||| .
Co-transfection  ||| S:1105 E:1121 ||| JJ
of  ||| S:1121 E:1124 ||| IN
miR-223-3p  ||| S:1124 E:1135 ||| CD
plasmid  ||| S:1135 E:1143 ||| NN
with  ||| S:1143 E:1148 ||| IN
FAM5C  ||| S:1148 E:1154 ||| CD
3 ||| S:1154 E:1155 ||| CD
' ||| S:1155 E:1156 ||| POS
UTR  ||| S:1156 E:1160 ||| NNP
dual-luciferase  ||| S:1160 E:1176 ||| NNP
plasmid  ||| S:1176 E:1184 ||| VBD
significantly  ||| S:1184 E:1198 ||| RB
inhibited  ||| S:1198 E:1208 ||| VBD
the  ||| S:1208 E:1212 ||| DT
luciferase  ||| S:1212 E:1223 ||| JJ
activity  ||| S:1223 E:1232 ||| NN
( ||| S:1232 E:1233 ||| -LRB-
P   ||| S:1233 E:1235 ||| NNP
< ||| S:1235 E:1236 ||| SYM
 0.01 ||| S:1236 E:1241 ||| NNP
) ||| S:1241 E:1242 ||| -RRB-
.  ||| S:1242 E:1244 ||| .
FAM5C ||| S:1244 E:1249 ||| NNP
,  ||| S:1249 E:1251 ||| ,
but  ||| S:1251 E:1255 ||| CC
not  ||| S:1255 E:1259 ||| RB
miR-223 ||| S:1259 E:1266 ||| CD
,  ||| S:1266 E:1268 ||| ,
is  ||| S:1268 E:1271 ||| VBZ
a  ||| S:1271 E:1273 ||| DT
risk  ||| S:1273 E:1278 ||| NN
factor  ||| S:1278 E:1285 ||| NN
for  ||| S:1285 E:1289 ||| IN
CI  ||| S:1289 E:1292 ||| NNP
in  ||| S:1292 E:1295 ||| IN
type  ||| S:1295 E:1300 ||| NN
2  ||| S:1300 E:1302 ||| CD
DM  ||| S:1302 E:1305 ||| NN
patients ||| S:1305 E:1313 ||| NNS
.  ||| S:1313 E:1315 ||| .
